Phase 4 Studies Support Alternative Pegloticase Dosing Regimens for Uncontrolled Gout, with Orrin Troum, MD

Published Date: 07 Aug 2025

The AGILE and FORWARD studies found comparable efficacy and safety with shorter doses and higher dose, monthly doses, compared to the pivotal MIRROR trial.

Read Full News

Latest News

Lupus Can Cost Young Women More Years Than Diabetes, HIV

Lupus contributes substantially to premature mortality in young women, with over 304,000 years of potential life lost in women aged 15-44 years from 2000 to 2015.

Pulmonary Fibrosis Video Diaries: Patient Experiences and Timely Diagnosis of IPF

Pulmonary Fibrosis Video Diaries: Patient Experiences and Timely Diagnosis of IPF

From Evidence to Action: Practical Strategies for FcRn Therapy in gMG

From Evidence to Action: Practical Strategies for FcRn Therapy in gMG

Next-Gen Therapies for gMG: The Science and Support for FcRn Antagonists

Next-Gen Therapies for gMG: The Science and Support for FcRn Antagonists

Strategies for Personalized CIDP Care: Patient Selection, Treatment Transition, and FcRn Therapy

Strategies for Personalized CIDP Care: Patient Selection, Treatment Transition, and FcRn Therapy

Transforming CIDP Management: Early Diagnosis, Pathophysiology, and the Emerging Role of FcRn Antagonists

Transforming CIDP Management: Early Diagnosis, Pathophysiology, and the Emerging Role of FcRn Antagonists

Todays Updates

EMA Backs Breast Cancer SERD After FDA No Vote

The recommendation follows phase 3 data showing longer progression-free survival when patients switched to camizestrant plus a CDK4/6 inhibitor.

Datopotamab Deruxtecan Earns New Breast Cancer Indication

The antibody drug conjugate was approved by the FDA for certain patients with triple-negative breast cancer.

Todays Updates

EMA Backs Breast Cancer SERD After FDA No Vote

The recommendation follows phase 3 data showing longer progression-free survival when patients switched to camizestrant plus a CDK4/6 inhibitor.

Datopotamab Deruxtecan Earns New Breast Cancer Indication

The antibody drug conjugate was approved by the FDA for certain patients with triple-negative breast cancer.

Latest News

Lupus contributes substantially to premature mortality in young women, with over 304,000 years of potential life lost in women aged 15-44 years from 2000 to 2015.

Pulmonary Fibrosis Video Diaries: Patient Experiences and Timely Diagnosis of IPF

From Evidence to Action: Practical Strategies for FcRn Therapy in gMG

Next-Gen Therapies for gMG: The Science and Support for FcRn Antagonists

Strategies for Personalized CIDP Care: Patient Selection, Treatment Transition, and FcRn Therapy

Transforming CIDP Management: Early Diagnosis, Pathophysiology, and the Emerging Role of FcRn Antagonists

News All Time

Osteoarthritis: Promising Drug Therapy Flops

No help from diacerein in randomized trial

Another B-Cell Drug for Lupus Hits the Mark

Phase III results put obinutuzumab in line for approval

Europe Does Better Than U.S. in Treating Spondyloarthritis, Survey Data Suggest

American patients report more symptoms and mostly don't agree with doctors on how they've fared

Medicare Coverage Appears Spotty for Newer Rheumatoid Arthritis Meds

Advantage plans do a better job than standalone Part D policies, albeit with important gaps

ICE Chief Hospitalized; Metastatic Colon Cancer at Age 26; TENS for Fibromyalgia

Health news and commentary gathered by MedPage Today staff

Dyspnea in Woman With RA Reveals a Diaphragmatic Lipoma

MRI can help differentiate these benign soft-tissue masses from more aggressive liposarcomas

What Caused This Patient's Recurring Eye and Ear Inflammation?

Prompt diagnosis of this rare progressive autoimmune disease may help preserve hearing, eyesight

What Caused Left-Sided Hearing Loss in This 65-Year-Old Man?

Numerous diagnostic procedures revealed tophaceous gout affecting the middle ear

EULAR: Docs Should Push Hard on Physical Activity for Arthritis Patients

We have met the enemy and it's the sofa, updated guideline indicates

Rheumatic Disease Drugs Help COVID Virus Stick Around Longer, Study Suggests

Lengthy viral antigen persistence far more common, regardless of prior vaccination

Drug Targeting TLRs in Cutaneous Lupus Looks Good in Mid-Stage Studies

— Dose-response signal appears in phase II trial, and all doses are better than placebo

Upadacitinib After TNF Inhibitor Failure Improves RA Control

In patients with active RA, switching to upadacitinib after failure of a single TNF inhibitor is more effective in reducing disease activity at 12 weeks than using a second TNF inhibitor adalimumab.

Early Anti-TNF to Prevent Difficult-to-Treat RA Gains Steam

The availability of TNF inhibitor biosimilars and the cost of treating ‘difficult-to-treat’ RA are making first-line TNF inhibition in early RA more attractive in the UK.

FDA Grants Breakthrough Therapy Designation to Ianalumab, First Potential Sjögren’s Targeted Therapy Victoria Johnson

Novartis plans to submit regulatory applications for ianalumab in early 2026.

FDA Updates Label for Reduced Osteoarthritis Risk With BEAR Implant Over ACL Reconstruction Victoria Johnson

FDA approves a label update for the BEAR implant, which was previously approved in 2020.

FDA Grants Priority Review to Efgartigimod, First Potential Therapy for Seronegative Myasthenia Gravis Victoria Johnson

argenx's efgartigimod-alfa therapy was approved for seropositive generalized myasthenia gravis in 2021.

Recommended News For You

In KRAS-mutated non-small cell lung cancer, glecirasib exhibits promising efficacy.

Radioligand Therapy Set to Transform Oncology Care

Accelerating the Evidence-Based Integration of Menin Inhibitors Into R/R AML Care: A Live Expert TheraTalk

Women are more susceptible to the stress caused by inflation.

Ultrasound imaging of breast cancer tumors offers noninvasive monitoring of treatment effectiveness

Waist circumference outshines BMI as obesity-related cancer risk marker in men, but not women

Women who miss their first mammogram face higher risk of breast cancer death, study finds

Recommended Articles For You

Mechanisms, Efficacy, and Survival Outcomes in AML, Squamous Cell Carcinoma, & Non-Hodgkin Lymphoma 

Phosphate Vs. Phosphorus: What Is The Difference? 

What Is A Normal Fibrinogen Level, And How Can It Affect Your Health 

Understanding Colon Cancer: Symptoms, Causes, and Treatment Options  

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Psychedelic Therapy Tied to Reduced Depression, Anxiety.

2.

New drug resistance mechanism in melanoma leptomeningeal disease revealed by study.

3.

Research finds stark disparities in treatment and survival time for people with pancreatic cancer

4.

Tumor characteristics found to differ for melanomas in children, teens and young adults

5.

Relationship-building key to addressing oncologist shortages in rural care

1.

Artificial Intelligence in Oncology: Current Trends, Challenges and Future Outlook

2.

Colon cancer: Risk factors, warning signs and treatment options 

3.

Exploring the Latest Advances in Hodgkin's Lymphoma Treatment

4.

Can We Repurpose BV-CHP for Better Outcomes in Peripheral T-Cell Lymphoma?

5.

The Expanding Horizon of PSMA: A Comparative Clinical Review of Theranostics in Prostate Cancer and Beyond

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Navigating the Brain Barrier: The CNS Challenge in ALK+ NSCLC

2.

Efficient Management of First line ALK-rearranged NSCLC - Part VIII

3.

Evolution in Treatment and Diagnosis of Lung Cancer- An Initiative from Manipal Hospitals

4.

Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part V

5.

INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot